SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma receives USFDA’s tentative approval for Cangrelor for Injection

08 Dec 2021 Evaluate

Gland Pharma has received a tentative approval from the United States Food and Drug Administration (USFDA) for Cangrelor for Injection, 50 mg/vial Single-Dose Vials. The company is amongst one of the first to files for this product and may be eligible for 180 days of generic drug exclusivity. The company will launch the product with its marketing partner on receipt of final approval.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.

Gland Pharma Share Price

1794.40 -1.40 (-0.08%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×